Novo Nordisk spells out the details behind a PhII NASH failure which reshaped its clinical plans
A little more than a year after Novo Nordisk and Gilead agreed to push into bigger studies of a three-drug combo in NASH, the Danish pharma has spelled out the data after running into a fresh obstacle on the monotherapy prospects for their big drug semaglutide — branded as Ozempic on the market.
The GLP-1 player, which has been racking up impressive results for diabetes and obesity in beating a path to major blockbuster status, failed a Phase II trial when tested against the liver disease. We knew that last fall when execs cited the setback in their Q3 call. And now we know more of the specifics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.